---

Neuromuscular Junction (NMJ): Anatomy, Physiology, and Anaesthetic Implications - Including Succinylcholine Phase I & II Block and NDMRs

---

PART 1: ANATOMY AND PHYSIOLOGY OF THE NMJ

Structure of the NMJ

• The axon of the motor neuron carries electrical signals from the anterior horn of the spinal cord to the muscle
• The nerve terminal contains all apparatus for ACh synthesis, storage, and release
• Choline acetyltransferase synthesizes ACh from choline + acetyl-CoA (from mitochondria)
• ACh is stored in synaptic vesicles (quanta), of which there are two pools: a readily releasable pool (VP2, close to active zones) and a reserve pool (VP1, tethered to actin/cytoskeleton by synapsin, synaptotagmin, spectrin)
• SNARE proteins (synaptobrevin/VAMP) dock vesicles at active zones and mediate exocytosis
• The nerve terminal also contains P/Q-type voltage-gated calcium channels and potassium channels

• ~20 nm wide
• Acetylcholinesterase (AChE) is densely anchored here - it hydrolyzes ACh into choline + acetate within milliseconds
• Choline is recycled back into the nerve terminal

• The postjunctional membrane has deep junctional folds that greatly increase surface area
• Nicotinic ACh receptors (nAChR) are densely packed at 10,000/μm² at the crests of the folds
• AChE is located in the depths of the folds

The Adult nAChR - Molecular Structure

• Two ACh molecules must bind simultaneously to the α-β and δ-α subunit interfaces for channel opening
• Channel allows Na⁺ influx and K⁺ efflux → end-plate potential (EPP)
• If EPP exceeds threshold, an action potential propagates along the muscle membrane → excitation-contraction coupling → muscle contraction
• The margin of safety at the NMJ is large: ~75% of receptors can be blocked before muscle twitch is visibly depressed

Normal Neuromuscular Transmission - Step by Step

1. Nerve action potential reaches terminal → Na⁺ influx → depolarization
2. Voltage-gated P/Q-type Ca²⁺ channels open → Ca²⁺ enters nerve terminal
3. Ca²⁺ triggers vesicle docking and exocytosis via SNARE proteins (synaptotagmin is Ca²⁺ sensor)
4. ACh quanta released into cleft; diffuses to nAChRs
5. Two ACh molecules bind to α subunits → channel opens → Na⁺/K⁺ flux → EPP
6. EPP threshold exceeded → muscle action potential → contraction
7. AChE rapidly hydrolyzes ACh → channel closes → repolarization → ready for next stimulus

• Ca²⁺ concentration doubles → 16-fold increase in ACh quantal release
• Mg²⁺ (used in pre-eclampsia) competes with Ca²⁺ at P channels → decreases ACh release → potentiates NDMRs
• Calcium channel blockers (verapamil, diltiazem) have minimal effect on normal transmission but may potentiate NDMRs at high doses

Prejunctional Receptors

• NDMRs block these receptors → impair ACh mobilization during repetitive stimulation → fade on TOF/tetanus
• Depolarizing agents (high dose succinylcholine) also block these → cause fade in Phase II block

---

PART 2: NEUROMUSCULAR MONITORING

---

PART 3: DEPOLARIZING NEUROMUSCULAR BLOCKADE - SUCCINYLCHOLINE (Suxamethonium)

Structure and Pharmacokinetics

• Succinylcholine → succinylmonocholine + choline → succinic acid + choline
• Only a small fraction reaches the NMJ (enzyme has enormous capacity)
• NOT hydrolyzed by AChE at the end plate
• Duration 5-10 minutes; block terminated by diffusion away from end plate

• Dibucaine inhibits normal pseudocholinesterase by 80% (dibucaine number ~80)
• Atypical enzyme: dibucaine number ~20 → succinylcholine duration dramatically prolonged (hours)
• Heterozygous: dibucaine number ~40-60 → moderately prolonged
• Clinical implication: family history of prolonged apnoea after suxamethonium warrants pseudocholinesterase activity and dibucaine number testing

---

PHASE I BLOCK (Depolarizing Block)

1. Succinylcholine binds nAChR → channels open → EPP generated → muscle fasciculations (unsynchronized contraction of motor units)
2. Voltage-dependent gates of adjacent perijunctional sodium channels open (initial muscle contraction visible as fasciculations)
3. Because succinylcholine is not cleared, end plate remains continuously depolarized
4. The time-dependent inactivation gate of perijunctional Na⁺ channels closes ("accommodation")
5. Na⁺ cannot flow through inactivated channels → no propagation of action potential beyond junctional zone
6. The perijunctional zone becomes a buffer, shielding distal muscle membrane
7. Result: flaccid paralysis despite end plate being depolarized

• End plate - depolarized by succinylcholine
• Perijunctional zone - Na⁺ channels in inactivated state
• Distal muscle - Na⁺ channels in resting state (can be stimulated directly by electricity)

---

PHASE II BLOCK (Desensitization / Dual Block)

1. Desensitization: The nAChR undergoes conformational change to a desensitized (closed-channel) state despite agonist occupation. In the desensitized state, the channel is closed and cannot be opened even when the agonist is bound. The receptor has high affinity for agonist but zero functionality. Desensitization may occur very rapidly (milliseconds after agonist exposure) or slowly.
2. Prejunctional receptor block: High concentrations of succinylcholine block the prejunctional α3-β2 nAChRs → impaired ACh mobilization → fade on tetanic/TOF stimulation (similar to NDMRs)
3. Channel block: Succinylcholine, as a slender molecule, can enter the open channel and physically block ion flow (open-channel block) - use-dependent, not reversed by anticholinesterases
4. Receptor internalisation: With very prolonged exposure, receptor downregulation may occur

• Total succinylcholine dose >3-4 mg/kg
• Prolonged infusion
• Volatile anaesthetics (halothane, isoflurane)
• Certain antibiotics (aminoglycosides)
• Local anaesthetics
• Phenothiazines
• Calcium channel blockers
• Pre-existing neuromuscular disease

• Discontinue succinylcholine infusion
• Confirm by nerve stimulator (TOF with fade)
• Controlled ventilation and wait for spontaneous recovery
• Neostigmine may be tried cautiously if TOF fade is well established and TOF ratio is improving but still <0.9 - effect is unpredictable; may transiently worsen before improving
• Most important: identify at-risk patients before using succinylcholine infusions

• Residual desensitized receptors from succinylcholine reduce the margin of safety
• Fewer functional receptors are available for NDMR to overcome

---

PART 4: NON-DEPOLARIZING MUSCLE RELAXANTS (NDMRs)

Mechanism of Action

Classification of NDMRs

---

Individual NDMRs - Pharmacology and Anaesthetic Implications

1. PANCURONIUM

• Dose: ED95 ~0.07 mg/kg; intubation 0.1 mg/kg
• Onset: 3-5 min | Duration: 60-90 min (long-acting)
• Metabolism/Elimination: 80% renal; 10-20% hepatic
• Side effects:
  • Tachycardia and hypertension - due to vagolytic effect (muscarinic M2 blockade at SA node) and sympathomimetic (norepinephrine reuptake inhibition)
  • Minimal histamine release
• Implications: Avoid in patients with ischaemic heart disease, hypertension; prolonged in renal/hepatic failure; cost-effective long-acting agent

2. VECURONIUM

• Dose: ED95 ~0.05 mg/kg; intubation 0.1 mg/kg
• Onset: 2-3 min | Duration: 25-40 min (intermediate)
• Metabolism: Hepatic (primarily) - 3-desacetyl vecuronium is active metabolite (~80% potency)
• Elimination: Biliary (60%) > renal (40%)
• Side effects:
  • No vagolytic effect - cardiovascular stability (ideal in cardiac surgery, elderly)
  • No histamine release
• Implications: Prolonged in hepatic failure; 3-desacetyl metabolite accumulates in ICU patients → prolonged weakness; reversed by neostigmine or sugammadex

3. ROCURONIUM

• Dose: ED95 ~0.3 mg/kg; intubation 0.6 mg/kg (RSI: 1.2 mg/kg)
• Onset: 60-90 seconds at 0.6 mg/kg; 60 seconds at 1.2 mg/kg - fastest NDMR onset
• Duration: 30-60 min (intermediate)
• Elimination: Primarily biliary/hepatic; 10-25% renal
• Side effects:
  • Slight vagolytic tendency at high doses
  • Minimal histamine release
  • Pain on injection
• Anaesthetic Implications:
  • The only NDMR that can substitute for succinylcholine in RSI (at 1.2 mg/kg, onset comparable)
  • Uniquely reversible by sugammadex at any depth of block
  • Prolonged in hepatic failure
  • Widely used for maintenance relaxation

4. ATRACURIUM

• Dose: ED95 ~0.23 mg/kg; intubation 0.4-0.5 mg/kg
• Onset: 2-3 min | Duration: 25-35 min
• Unique Metabolism: Hofmann Elimination + Ester Hydrolysis
  • Hofmann elimination - spontaneous non-enzymatic degradation at physiological pH and temperature (temperature and pH dependent)
  • Produces laudanosine (a CNS stimulant - theoretical seizure risk at very high doses; not clinically significant in standard doses)
  • No dependence on renal or hepatic function
• Side effects:
  • Histamine release (dose-dependent) - can cause bronchospasm, hypotension, flushing; give slowly
• Implications: Drug of choice in patients with significant renal AND hepatic failure; hypothermia prolongs block (Hofmann slowed); avoid rapid IV bolus

5. CISATRACURIUM

• Dose: ED95 ~0.05 mg/kg; intubation 0.15-0.2 mg/kg
• Onset: 3-5 min | Duration: 40-75 min
• Metabolism: Hofmann elimination (primarily; ~80%); minimal ester hydrolysis
• One of 10 isomers of atracurium; 3-4x more potent than atracurium
• Side effects:
  • Negligible histamine release - preferred over atracurium in asthmatics/atopic patients
  • Less laudanosine production (lower doses used)
• Implications: Preferred for organ failure patients, ICU (least histamine release, organ-independent elimination), prolonged mechanical ventilation

6. MIVACURIUM

• Dose: ED95 ~0.08 mg/kg; intubation 0.15-0.2 mg/kg
• Onset: 2-3 min | Duration: 15-20 min (shortest-acting NDMR)
• Metabolism: Plasma cholinesterase (pseudocholinesterase) - like succinylcholine
• Side effects:
  • Histamine release (dose-dependent) if given rapidly
  • Prolonged in pseudocholinesterase deficiency (same risk as succinylcholine)
• Implications: Useful for short procedures where tracheal intubation is needed but succinylcholine is contraindicated; no need for reversal in most cases; avoid in pseudocholinesterase deficiency

---

Factors Modifying NDMR Response

• Volatile anaesthetics (isoflurane > enflurane > halothane > N₂O) - potentiate dose-dependently
• Aminoglycoside antibiotics (competitive at NMJ + reduce presynaptic Ca²⁺ entry)
• Hypokalemia, hypermagnesaemia, hypocalcaemia, acidosis, hypothermia
• Renal failure (pancuronium, vecuronium, rocuronium)
• Hepatic failure (vecuronium, rocuronium, pancuronium)
• Prior succinylcholine (desensitization → enhanced sensitivity)
• Myasthenia gravis (reduced functional receptors → exquisite sensitivity)

• Prior burns/immobilisation/denervation (upregulation of extrajunctional receptors including γ-subunit and α7 receptors)
• Upper motor neuron lesions
• Carbamazepine (chronic use induces receptor changes)
• Alkalosis, hypercalcaemia, hyperkalaemia

---

Reversal of NDMRs

Anticholinesterases

• Neostigmine (0.04-0.07 mg/kg) + glycopyrrolate; or pyridostigmine
• Inhibit AChE → accumulation of ACh → competitive displacement of NDMR
• Only effective at moderate block - deep block (TOF count <2, PTC <10) cannot be reliably reversed
• Ceiling effect: cannot produce more ACh than the system can provide
• Always co-administer anticholinergic (glycopyrrolate 0.2 mg per 1 mg neostigmine) to prevent muscarinic effects (bradycardia, bronchospasm, hypersalivation)

Sugammadex - Cyclodextrin Encapsulation

• Modified γ-cyclodextrin that encapsulates rocuronium and vecuronium (steroidal NDMRs) in a 1:1 ratio with high affinity
• Reduces free plasma NDMR → concentration gradient causes NDMR to diffuse away from NMJ into plasma → immediate reversal
• Key advantage: Works at ANY depth of block (unlike neostigmine)
  • 2 mg/kg for shallow block (spontaneous recovery to T2)
  • 4 mg/kg for deep block (1-2 PTC, no TOF response)
  • 16 mg/kg for immediate reversal after 1.2 mg/kg rocuronium (RSI reversal)
• No muscarinic effects; no ceiling
• Adverse effects: hypersensitivity/anaphylaxis (rare), bradycardia
• Renal failure: sugammadex-rocuronium complex excreted renally; complex is stable and inactive, but elimination delayed - use with caution in severe renal impairment

---

PART 5: SPECIFIC ANAESTHETIC IMPLICATIONS OF SUCCINYLCHOLINE (BEYOND PHASE I/II)

Contraindications and Hazards

• Burns (>24-48 hours old, until fully healed - peak risk 7-10 days)
• Massive trauma/crush injury (>24-48 hours)
• Spinal cord injury (>24-48 hours - extrajunctional upregulation)
• Prolonged immobilisation
• Denervating conditions: Guillain-Barré, severe Parkinson's, stroke, encephalitis, tetanus
• Myopathies: Duchenne muscular dystrophy (high risk of rhabdomyolysis too)
• Severe intraabdominal infection/sepsis (>3-5 days)

• Succinylcholine is a trigger for MH along with all volatile agents
• MH: autosomal dominant disorder (RYR1 mutations); uncontrolled Ca²⁺ release from sarcoplasmic reticulum → hypermetabolic state
• Management: stop trigger, dantrolene 2.5 mg/kg IV (blocks RyR1)
• Succinylcholine should never be used routinely in paediatric patients (unknown myopathy risk)

• Extraocular muscles are tonic/multiply innervated; lack accommodation
• Succinylcholine → sustained contracture of extraocular muscles → IOP rises 6-12 mmHg
• Relative contraindication in penetrating eye injury (though risk of aspiration in full stomach may outweigh IOP risk)
• Alpha-conotoxin-sensitive conventional AChRs + desensitization-resistant receptors on extraocular muscles explain this

• Abdominal fasciculations → raised intragastric pressure
• However, concurrent rise in lower oesophageal sphincter tone prevents increased regurgitation risk - no net increase in aspiration risk

• Muscle fasciculations → transient rise in ICP via raised intrathoracic and venous pressure
• Precurarisation (small dose NDMR 3-5 min before) reduces fasciculations

• Unsynchronised fasciculations cause myoglobinemia and muscle pain (especially in young ambulatory patients)
• Reduced by: precurarisation with rocuronium 0.06 mg/kg, pretreatment with NSAIDs or benzodiazepines

• Succinylcholine can cause sinus bradycardia (especially in children, or with repeated doses) via muscarinic stimulation
• Prevented by atropine (0.02 mg/kg IV pre-treatment in children)

• Pseudocholinesterase deficiency (genetic or acquired: liver disease, renal disease, malnutrition, pregnancy, echothiophate eye drops, organophosphate poisoning)
• Management: controlled ventilation until spontaneous recovery; fresh frozen plasma (contains pseudocholinesterase)

---

PART 6: CLINICAL PHARMACOLOGY COMPARISON TABLE

---

PART 7: SPECIAL SITUATIONS AND RECEPTOR UPREGULATION

Extrajunctional Receptor Upregulation

• Succinylcholine → catastrophic K⁺ release from these widespread receptors (absolute contraindication)
• Resistance to NDMRs - α7 receptors:
  • Do not desensitize with choline
  • Have lower affinity for NDMRs (require 3/5 subunits blocked to inhibit; conventional receptor needs only 1/2)
  • Result: higher doses of NDMR needed; unpredictable responses

Myasthenia Gravis

• Autoimmune destruction of postjunctional nAChRs (antibodies to α subunit)
• Reduced receptor number → reduced safety margin
• Exquisitely sensitive to NDMRs (use 10-20% of normal dose, carefully titrated)
• Resistant to succinylcholine (fewer receptors to depolarize, but prolonged due to cholinesterase deficiency from pyridostigmine therapy)

Eaton-Lambert Myasthenic Syndrome

• Antibodies against presynaptic voltage-gated Ca²⁺ channels (P/Q type)
• Decreased ACh release
• Sensitive to BOTH depolarizing and nondepolarizing agents - use extreme caution, very small doses

ICU-Acquired Neuromuscular Weakness

• Prolonged NDMR infusion in ICU + corticosteroids → critical illness myopathy and neuropathy
• 3-desacetyl vecuronium (active metabolite of vecuronium) accumulates in renal failure
• Use peripheral nerve stimulator monitoring to prevent overdosing; cisatracurium preferred in ICU

---

SUMMARY POINTS FOR EXAM

1. NMJ transmits via ACh → nAChR (pentameric, 2 ACh required) → EPP → muscle contraction; margin of safety is large (75% blockade needed before twitch visible)
2. Succinylcholine Phase I = depolarizing block; fasciculations; no TOF fade; worsen with anticholinesterases; direct muscle stimulation works
3. Succinylcholine Phase II = desensitization/dual block after prolonged exposure; TOF fade present; resembles NDMR; may partially reverse with neostigmine; best managed with controlled ventilation
4. NDMRs = competitive antagonists; reversed by anticholinesterases (moderate block) or sugammadex (any depth, steroidal agents only)
5. Rocuronium 1.2 mg/kg + sugammadex 16 mg/kg = viable alternative to succinylcholine-based RSI
6. Succinylcholine contraindications: burns >48h, cord injury >48h, denervation, hyperkalaemia, MH susceptibility, myopathies
7. Atracurium/Cisatracurium = organ-independent elimination (Hofmann) → drug of choice in multi-organ failure
8. Mg²⁺ potentiates all neuromuscular blockers by reducing presynaptic Ca²⁺ entry; monitor closely in pre-eclamptic patients
9. Residual block (TOF ratio <0.9) is a real clinical hazard → aspiration, hypoxia; use nerve stimulator routinely and ensure TOF ratio >0.9 before extubation

---

---

How Succinylcholine (Suxamethonium) and NDMRs Act on the NMJ

---

Quick Recap: The Normal NMJ

1. Nerve action potential → Ca²⁺ enters nerve terminal → ACh vesicles released
2. ACh diffuses across cleft → binds to both α-subunits of the nAChR (pentameric: α₂βδε)
3. Channel opens → Na⁺/Ca²⁺ influx, K⁺ efflux → end-plate potential (EPP)
4. EPP exceeds threshold → muscle action potential → contraction
5. Acetylcholinesterase (AChE) rapidly destroys ACh → channel closes → end plate repolarizes → ready for next impulse

---

SUCCINYLCHOLINE (Suxamethonium) - Depolarizing Agent

What it is structurally

Step-by-step action at the NMJ

• A voltage-dependent activation gate (opens when depolarization occurs)
• A time-dependent inactivation gate (closes shortly after the activation gate opens)

Clinically important: Because distal muscle Na⁺ channels are in the resting state, direct electrical stimulation of muscle produces contraction even during succinylcholine paralysis. This distinguishes succinylcholine block from muscle disease.

Summary of succinylcholine action at NMJ

Succinylcholine → binds nAChR α-subunits (agonist)
        ↓
Channel opens → EPP → fasciculations
        ↓
Not destroyed by AChE → remains in cleft
        ↓
Sustained end-plate depolarization
        ↓
Perijunctional Na⁺ channel inactivation (accommodation)
        ↓
No action potential propagation → FLACCID PARALYSIS

Why anticholinesterases worsen Phase I succinylcholine block

---

NDMRs (Non-Depolarising Muscle Relaxants)

What they are structurally

Step-by-step action at the NMJ

• ACh (agonist - wants to open the channel)
• NDMR (antagonist - blocks the opening)

The large margin of safety at the NMJ means ~75% of receptors must be blocked before any visible twitch depression occurs.

Why anticholinesterases reverse NDMR block

Summary of NDMR action at NMJ

NDMR → binds α-subunit(s) of nAChR (pure antagonist - no channel activation)
        ↓
ACh cannot occupy both α-subunits simultaneously
        ↓
Channel stays CLOSED
        ↓
No end-plate potential
        ↓
No muscle action potential → FLACCID PARALYSIS (no fasciculations)
        ↓
Reversed by: ACh accumulation (neostigmine) OR
             cyclodextrin encapsulation (sugammadex for rocuronium/vecuronium)

---

Side-by-Side Comparison

---

Why NDMRs Show TOF Fade but Succinylcholine Does Not

• NDMRs block prejunctional α3-nAChRs on the nerve terminal → impair ACh mobilization from the reserve pool during repetitive stimulation → progressively less ACh released with each stimulus → T4 < T3 < T2 < T1 = fade
• Succinylcholine (Phase I) does not produce fade at clinical doses. The end plate is uniformly depolarized; each stimulus sees the same degree of block. The ACh release mechanism is not significantly impaired → no fade. Only in Phase II block (prolonged succinylcholine) does fade appear, because then prejunctional receptors also get blocked.

---